EP1085872A4 - INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B - Google Patents

INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B

Info

Publication number: EP1085872A4
Authority: EP; European Patent Office
Prior art keywords: inhibitors; transcription factor; transcription; factor
Prior art date: 1998-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP99930459A

Other languages

German (de)

French (fr)

Other versions

EP1085872A1 (en

Inventor

James F Callahan

Marie C Chabot-Fletcher

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Corp

Original Assignee

SmithKline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-18

Publication date

2003-04-16

1999-06-18 Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp

2001-03-28 Publication of EP1085872A1 publication Critical patent/EP1085872A1/en

2003-04-16 Publication of EP1085872A4 publication Critical patent/EP1085872A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

EP99930459A 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B Withdrawn EP1085872A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9001698P	1998-06-19	1998-06-19
US90016P		1998-06-19
PCT/US1999/013897 WO1999065495A1 (en)	1998-06-19	1999-06-18	INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (2)

Publication Number	Publication Date
EP1085872A1 EP1085872A1 (en)	2001-03-28
EP1085872A4 true EP1085872A4 (en)	2003-04-16

Family

ID=22220761

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99930459A Withdrawn EP1085872A4 (en)	1998-06-19	1999-06-18	INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B

Country Status (17)

Country	Link
EP (1)	EP1085872A4 (en)
JP (1)	JP2002518333A (en)
KR (1)	KR20010052990A (en)
CN (1)	CN1306428A (en)
AR (1)	AR019871A1 (en)
AU (1)	AU4699699A (en)
BR (1)	BR9911151A (en)
CA (1)	CA2335293A1 (en)
CO (1)	CO5080752A1 (en)
CZ (1)	CZ20004760A3 (en)
HU (1)	HUP0102492A2 (en)
IL (1)	IL140324A0 (en)
NO (1)	NO20006452L (en)
PL (1)	PL345577A1 (en)
TR (1)	TR200003779T2 (en)
WO (1)	WO1999065495A1 (en)
ZA (1)	ZA200007448B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122010000048I1 (en)	1996-12-23	2011-05-05	Immunex Corp	LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CA2328140C (en)	1998-05-14	2012-03-13	Immunex Corporation	Method of inhibiting osteoclast activity
IL150763A0 (en) *	2000-01-24	2003-02-12	Genzyme Corp	Jak/stat inhibitors and pharmaceutical compositions containing the same
US20060148732A1 (en) *	2000-11-17	2006-07-06	Gutterman Jordan U	Inhibition of NF-kappaB by triterpene compositions
PT2087908T (en)	2001-06-26	2018-07-16	Amgen Inc	OPGL ANTIBODIES
US7425580B2 (en)	2004-05-19	2008-09-16	Wyeth	(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US7812018B2 (en)	2006-02-16	2010-10-12	Millennium Pharmaceuticals, Inc.	Alpha carbolines and uses thereof
PL2366699T3 (en)	2008-10-02	2013-12-31	Asahi Kasei Pharma Corp	8-substituted isoquinoline derivative and use thereof
US9127016B2 (en)	2009-03-20	2015-09-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Small molecule inhibitors of Dusp6 and uses therefor
WO2011014825A2 (en)	2009-07-31	2011-02-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antiangiogenic small molecules and methods of use
US10160705B2 (en)	2011-02-10	2018-12-25	University of Pittsburgh—of the Commonwealth System of Higher Education	Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en)	2012-10-31	2014-05-08	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

1998
- 1998-06-18 HU HU0102492A patent/HUP0102492A2/en unknown
1999
- 1999-06-17 CO CO99037918A patent/CO5080752A1/en unknown
- 1999-06-18 EP EP99930459A patent/EP1085872A4/en not_active Withdrawn
- 1999-06-18 CA CA002335293A patent/CA2335293A1/en not_active Abandoned
- 1999-06-18 TR TR2000/03779T patent/TR200003779T2/en unknown
- 1999-06-18 PL PL99345577A patent/PL345577A1/en not_active Application Discontinuation
- 1999-06-18 CN CN99807572A patent/CN1306428A/en active Pending
- 1999-06-18 AU AU46996/99A patent/AU4699699A/en not_active Abandoned
- 1999-06-18 AR ARP990102952A patent/AR019871A1/en unknown
- 1999-06-18 CZ CZ20004760A patent/CZ20004760A3/en unknown
- 1999-06-18 BR BR9911151-9A patent/BR9911151A/en not_active Application Discontinuation
- 1999-06-18 WO PCT/US1999/013897 patent/WO1999065495A1/en not_active Application Discontinuation
- 1999-06-18 JP JP2000554375A patent/JP2002518333A/en not_active Withdrawn
- 1999-06-18 IL IL14032499A patent/IL140324A0/en unknown
- 1999-06-18 KR KR1020007014385A patent/KR20010052990A/en not_active Application Discontinuation
2000
- 2000-12-13 ZA ZA200007448A patent/ZA200007448B/en unknown
- 2000-12-18 NO NO20006452A patent/NO20006452L/en not_active Application Discontinuation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAURY, GEORGES ET AL: "Mobile keto-allyl systems. VII. Amine-exchange reactions in the indanone-indenone series", JOURNAL OF ORGANIC CHEMISTRY (1968), 33(5), 1907-13, XP002230731 *
PEARSON, BARRY D. ET AL: "Elimination reactions of.alpha.-halogenated ketones. IX. Comparison of the reactions of 2-bromo-2-(.alpha.-bromobenzyl)1-indanone with those of 2-bromo-2-(.alpha.-bromobenzyl)-3,3dimethyl-l-indanone", J. ORG. CHEM. (1962), 27, 3038-44, XP002230730 *
See also references of WO9965495A1 *

Also Published As

Publication number	Publication date
ZA200007448B (en)	2001-12-12
HUP0102492A2 (en)	2001-11-28
KR20010052990A (en)	2001-06-25
AR019871A1 (en)	2002-03-20
NO20006452L (en)	2001-02-16
BR9911151A (en)	2001-03-06
IL140324A0 (en)	2002-02-10
CA2335293A1 (en)	1999-12-23
JP2002518333A (en)	2002-06-25
CO5080752A1 (en)	2001-09-25
WO1999065495A1 (en)	1999-12-23
EP1085872A1 (en)	2001-03-28
PL345577A1 (en)	2001-12-17
NO20006452D0 (en)	2000-12-18
CZ20004760A3 (en)	2001-08-15
CN1306428A (en)	2001-08-01
TR200003779T2 (en)	2001-06-21
AU4699699A (en)	2000-01-05

Publication	Publication Date	Title
EP1085848A4 (en)	2004-09-08	Inhibitors of transcription factor nf-kappa b
AU4677399A (en)	1999-12-30	Inhibitors of H+K+-ATPase
ZA973146B (en)	1998-04-14	Prodrugs of COX-2 inhibitors.
IL137540A0 (en)	2001-07-24	Inhibitors of phospholipase a2
AU4429799A (en)	1999-12-30	Inhibitors of p38
PL343611A1 (en)	2001-08-27	Inhibitors of caspases
AP9701054A0 (en)	1997-10-31	Inhibitors of cycteine protease
IL139127A0 (en)	2001-11-25	Process for synthesizing cox -2 inhibitors
PL331338A1 (en)	1999-07-05	Thiosulphonamidic metaloprotease inhibitors
PL331856A1 (en)	1999-08-16	Heterocyclic inhibitors of metaloprotease
AU6477498A (en)	1998-11-12	Scale inhibitors
GB0025782D0 (en)	2000-12-06	Use of inhibitors
IL118657A0 (en)	1996-10-16	Inhibitors for picornavirus proteases
PL331803A1 (en)	1999-08-02	Bidonoric metaloprotease inhibitors
PL328665A1 (en)	1999-02-15	Inhibitors of serinic protease
EP1085872A4 (en)	2003-04-16	INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B
TW470199U (en)	2001-12-21	Structure of maintaining portion for cymbals
AU2277597A (en)	1997-09-10	New inhibitors of sh2-mediated processes
AU5673099A (en)	2000-03-06	Inhibitors of amyloid formation
IL134210A0 (en)	2001-04-30	Use of transcription factor brn-3a
AU9119998A (en)	2000-03-21	Method of time-to-talk calculation
AU4021700A (en)	2000-10-09	Methods of use of beta1-integrin inhibitors
GB0029539D0 (en)	2001-01-17	Method for identifying modulatorss of transcription
AU2002221882A1 (en)	2002-06-03	Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2001276049A1 (en)	2002-02-05	Method of enabling the spacing of metal units

Legal Events

Date	Code	Title	Description
2001-02-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-03-28	17P	Request for examination filed	Effective date: 20001213
2001-03-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-03-28	AX	Request for extension of the european patent	Free format text: SI PAYMENT 20001213
2003-04-02	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61P 29/00 B Ipc: 7A 61P 37/06 B Ipc: 7A 61P 35/00 B Ipc: 7A 61P 31/18 B Ipc: 7A 61P 19/10 B Ipc: 7A 61P 19/02 B Ipc: 7A 61P 17/06 B Ipc: 7A 61P 11/06 B Ipc: 7A 61K 31/135 B Ipc: 7A 61K 31/40 B Ipc: 7A 61K 31/445 B Ipc: 7A 61K 31/495 B Ipc: 7A 61K 31/535 A
2003-04-16	A4	Supplementary search report drawn up and despatched	Effective date: 20030228
2003-06-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2003-07-23	18D	Application deemed to be withdrawn	Effective date: 20030103
2008-01-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1035668 Country of ref document: HK